Arighno Das1, Ahsun Riaz1, Ahmed Gabr1, Rehan Ali1, Ronald Mora1, Ali Al Asadi1, Samdeep Mouli1, Robert J Lewandowski1,2,3, Riad Salem4,5,6. 1. Department of Radiology, Section of Interventional Radiology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. 2. Department of Surgery, Division of Transplant Surgery, Northwestern University, Chicago, IL, USA. 3. Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA. 4. Department of Radiology, Section of Interventional Radiology, Northwestern University Feinberg School of Medicine, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. r-salem@northwestern.edu. 5. Department of Surgery, Division of Transplant Surgery, Northwestern University, Chicago, IL, USA. r-salem@northwestern.edu. 6. Department of Medicine, Division of Oncology, Northwestern University, Chicago, IL, USA. r-salem@northwestern.edu.
Abstract
BACKGROUND: Technetium-99m macroaggregated albumin is used to estimate lung shunt fraction (LSF) prior to yttrium-90 (Y90). Studies have debated the safety and efficacy of Y90 in patients with LSF > 15%. We aimed to assess the role of Y90 in hepatocellular carcinoma (HCC) with LSF > 15%. METHODS: With IRB approval, we searched our prospectively acquired database of HCC patients with Y90 treated with LSF > 15%. Median LSF and liver and lung doses were calculated. The response was assessed using RECIST. Overall survival (OS) was calculated from date of first Y90. RESULTS: A total of 103 HCC patients underwent Y90. The median baseline LSF was 24.4% (IQR 18.1-28.8). Patients exhibited multifocal disease (59/103, 60%) and median tumor size of 7.85 cm (IQR 5.2, 10.57). BCLC class was A, B, C, and D in 7 (7%), 5 (5%), 85 (83%), and 6 (6%) patients, respectively. The median liver dose was 84.6 Gy (IQR 57.4, 107.55). The median lung dose per session and cumulatively was 22.9 Gy (IQR 15-28) and 29.5 Gy (IQR 20.5-44.3). Thirty-three patients (32%) demonstrated partial response, 57 stable disease, and 13 (13%) had progressive disease. The median OS was 7.3 months (95% CI 5.3, 11.47). Twenty patients (19%) had non-specific pulmonary symptoms (cough, shortness of breath, wheezing) in the 1-year post-Y90. The median time to the appearance of non-specific pulmonary symptoms was 63 days (range 7-224). Thoracic imaging demonstrated no pulmonary fibrosis/injury following treatment in any patient. CONCLUSION: Y90 can be performed in patients with LSF > 15%. The RECIST response was identified in 32% of the patients. In isolation, LSF > 15% should not deter from treatment with Y90.
BACKGROUND: Technetium-99m macroaggregated albumin is used to estimate lung shunt fraction (LSF) prior to yttrium-90 (Y90). Studies have debated the safety and efficacy of Y90 in patients with LSF > 15%. We aimed to assess the role of Y90 in hepatocellular carcinoma (HCC) with LSF > 15%. METHODS: With IRB approval, we searched our prospectively acquired database of HCC patients with Y90 treated with LSF > 15%. Median LSF and liver and lung doses were calculated. The response was assessed using RECIST. Overall survival (OS) was calculated from date of first Y90. RESULTS: A total of 103 HCC patients underwent Y90. The median baseline LSF was 24.4% (IQR 18.1-28.8). Patients exhibited multifocal disease (59/103, 60%) and median tumor size of 7.85 cm (IQR 5.2, 10.57). BCLC class was A, B, C, and D in 7 (7%), 5 (5%), 85 (83%), and 6 (6%) patients, respectively. The median liver dose was 84.6 Gy (IQR 57.4, 107.55). The median lung dose per session and cumulatively was 22.9 Gy (IQR 15-28) and 29.5 Gy (IQR 20.5-44.3). Thirty-three patients (32%) demonstrated partial response, 57 stable disease, and 13 (13%) had progressive disease. The median OS was 7.3 months (95% CI 5.3, 11.47). Twenty patients (19%) had non-specific pulmonary symptoms (cough, shortness of breath, wheezing) in the 1-year post-Y90. The median time to the appearance of non-specific pulmonary symptoms was 63 days (range 7-224). Thoracic imaging demonstrated no pulmonary fibrosis/injury following treatment in any patient. CONCLUSION: Y90 can be performed in patients with LSF > 15%. The RECIST response was identified in 32% of the patients. In isolation, LSF > 15% should not deter from treatment with Y90.
Authors: Laura Kulik; Michael Vouche; Sean Koppe; Robert J Lewandowski; Mary F Mulcahy; Daniel Ganger; Ali Habib; Jennifer Karp; Patrice Al-Saden; Mario Lacouture; Jonathan Cotliar; Michael Abecassis; Talia Baker; Riad Salem Journal: J Hepatol Date: 2014-03-27 Impact factor: 25.083
Authors: Ahsun Riaz; Khairuddin Memon; Frank H Miller; Paul Nikolaidis; Laura M Kulik; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Vanessa L Gates; Mary F Mulcahy; Talia Baker; Ed Wang; Ramona Gupta; Ritu Nayar; Al B Benson; Michael Abecassis; Reed Omary; Riad Salem Journal: J Hepatol Date: 2010-10-23 Impact factor: 25.083
Authors: Riad Salem; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Saad Ibrahim; Bassel Atassi; Talia Baker; Vanessa Gates; Frank H Miller; Kent T Sato; Ed Wang; Ramona Gupta; Al B Benson; Steven B Newman; Reed A Omary; Michael Abecassis; Laura Kulik Journal: Gastroenterology Date: 2009-09-18 Impact factor: 22.682
Authors: Charles H Cha; Leyo Ruo; Yuman Fong; William R Jarnagin; Jinru Shia; Leslie H Blumgart; Ronald P DeMatteo Journal: Ann Surg Date: 2003-09 Impact factor: 12.969
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Minzhi Xing; Steven Lahti; Nima Kokabi; David M Schuster; Juan C Camacho; Hyun S Kim Journal: Clin Nucl Med Date: 2016-01 Impact factor: 7.794
Authors: M Weber; M Lam; C Chiesa; M Konijnenberg; M Cremonesi; P Flamen; S Gnesin; L Bodei; T Kracmerova; M Luster; E Garin; K Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-11 Impact factor: 9.236